论文部分内容阅读
通过考察阿托伐他汀(atorvastatin, ATO) 对自发性高血压大鼠(spontaneously hypertensive rats, SHR) 肾脏炎性损害的影响, 探讨了 ATO 对高血压肾脏并发症的防治作用。将4周龄SHR分为高血压模型组和ATO治疗组(8mg/kg),以同周龄的Wistar-Kyoto大鼠为正常对照。灌胃给药8周后, 采用酶联免疫法(enzyme linked immunosorbent assay)测定血浆和肾组织血管紧张素Ⅱ(angiotensin, AngⅡ)含量;测定诱导性一氧化氮合酶(inducible nitric oxide synthase, iNOS)及细胞间粘附分子-1(intercellular adhesion molecule-1, ICAM-1) 的蛋白表达和亚硝酸阴离子(nitrite, NO2-)含量,以评价肾脏炎症状态; 以苏木素伊红(hematoxylin and eosin)和过碘酸六胺银染色(periodic acid-silver metheramine) 染色示SHR肾小球和肾间质形态学病变,并以尿蛋白含量为指标衡量肾脏功能。结果显示,ATO给药后显著降低了SHR肾组织 AngⅡ含量;肾组织iNOS和ICAM-1的蛋白表达及NO2-含量明显降低,同时伴随着SHR肾脏病理形态的改善和肾功能的提高。该研究表明,ATO可显著改善SHR肾脏炎性损害,ATO可能在高血压肾脏并发症的防治方面有一定的疗效。
To investigate the effect of atorvastatin (ATO) on renal inflammatory injury in spontaneously hypertensive rats (SHR) and to explore the preventive and therapeutic effects of ATO on renal complications in hypertensive rats. Four-week-old SHRs were divided into hypertensive model group and ATO treatment group (8mg / kg), Wistar-Kyoto rats of the same age as the normal control. After intragastric administration for 8 weeks, the contents of angiotensin (AngⅡ) in plasma and kidney tissue were determined by enzyme linked immunosorbent assay. The expressions of inducible nitric oxide synthase (iNOS) ) And intercellular adhesion molecule-1 (ICAM-1) protein expression and nitrite (NO2-) content were measured to evaluate the status of renal inflammation. The hematoxylin and eosin And periodic acid-silver metheramine staining of SHR glomerular and renal interstitial morphological lesions, and urinary protein content as an indicator of renal function. The results showed that ATO administration significantly reduced the content of AngⅡin SHR kidney tissue; the protein expression of iNOS and ICAM-1 in kidney tissue and the content of NO2- significantly decreased, accompanied by the improvement of kidney pathological morphology and renal function in SHR. The study shows that ATO can significantly improve SHR renal inflammatory damage, ATO may have some effect in the prevention and treatment of hypertensive renal complications.